Experimental validation demonstrated robust tumor-targeted delivery and the potent gene silencing efficacy of the EGFR- and survivin-targeting siRNAs, resulting in a significant reduction in tumor size and the inhibition of tumor-associated vasculature. This evidence concerns the gene EGFR and neoplasm.